Core Viewpoint - Nanhua Financial (00619) has signed a memorandum of understanding with a company registered in China to establish a joint venture focused on AI-enabled biotechnology, aiming to diversify its business and tap into high-growth markets [1] Group 1: Joint Venture Details - The joint venture will focus on three main areas: enabling technology using AI for data analysis and research, scientific research for clinical applications, and developing end products for drug pipelines and clinical applications [1] - The joint venture aims to establish an AI drug development platform, provide related technical services, and develop AI efficacy prediction platforms for global beauty clients [1] Group 2: Strategic Expansion - The company is actively seeking strategic opportunities in high-tech sectors while consolidating its existing financial business [1] - The investment in AI-enabled biotechnology is a key step in the company's diversification strategy, which aims to mitigate existing business risks and create new revenue and profit sources [1]
南华金融拟设立合营公司进军AI制药、美妆科技及抗衰老消费市场等高增长领域